UK MHRA grants Marketing Authorisation to Marksans Pharma’s arm

05 Feb 2019 Evaluate

UK MHRA has granted Marketing Authorisation to Marksans Pharma’s wholly owned subsidiary, Relonchem, UK for Loratadine 5mg/5ml Oral Solution for the UK markets. The product will be manufactured in its UK facility. Loratadine Oral Solution is indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children.

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.

Marksans Pharma Share Price

183.95 -3.95 (-2.10%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×